Genetic Counseling Program

Untitled Document

Treatment Options for Patients with MPSII (Hunter Syndrome) and MPS III (Sanfilippo Syndrome): How Do Families Make the Choice?  By Amanda Padro

Introduction:  Despite a lack of evidence supporting the effectiveness of hematopoeitic stem cell transplantations (HSCTs) in patients with MPS II or MPS III, great variability in symptom penetrance amongst affected individuals, varying prognoses on a case by case basis, higher life expectancies in some patients, and high morbidity and mortality rates inherent in HSCT procedures, families choose to pursue HSCT as a treatment option.  The prevalence of HSCTs being performed on patients with MPS II or MPS III is unknown due to lack of data and the rarity of the disorder.   With the recent addition of ERT as a viable option for patients with MPS II, the questions addressed in this study included: Is the patient population informed about these possible therapies?,  Which therapies, if any, are they pursuing?, and How are they making these decisions?  Methods:  A non-validated survey developed specifically for this study was sent to families making decisions regarding MPS II and MPS III through the National MPS Society.  Quantitative and qualitative descriptive analysis was utilized to highlight patterns in how informed these families are regarding HSCT and ERT (for MPS II), and how these families are making decisions regarding treatment options.  Results:  66.7% of respondents to the MPS II survey and 53.8% of respondents to the MPS III survey reported knowledge of HSCT as a treatment option for these conditions.  11.1% and 5.8% of these MPS II and MPS III survey respondents reported choosing HSCT, respectively.  100% of MPS II survey respondents reported knowledge of ERT, and 69.4% chose ERT as a treatment option for the condition.  Factors important to decisions regarding treatment options included risks, procedure logistics, candidacy, potential benefits, and presence or absence of medical evidence of efficacy.  Conclusion:  More families coping with MPS II were aware of HSCT as a treatment option, but more families coping with MPS III actually considered the option as a treatment for their child.  While majority of respondents from both populations do not choose to pursue HSCT, a small subset of these families report the perception that this is the only option available to them, and they feel that they must try something to prolong or improve their child’s life.  A majority of MPS II survey respondents reported pursuing ERT as a treatment option for their child.

Back to Class of 2007 Capstone Projects

 

 

 

 

 

 

 

 
  • About Us
  • Admission Requirements
  • Curriculum
  • Clinical Rotations
  • Resources
  • Make a Gift


  • "I chose to attend UNCG because of its shared learning environment and the access to some of the leading institutions in the country. "



  • "UNCG is a great fit for me. The program directors have extensive experience in the world of genetic counseling and provide you with opportunities to work with some of the best medical centers in the country. Our location allows us to have expert guest lecturers, many of whom you also get to work alongside or observe in your clinical rotations in your second year. We also have some really wonderful and unique opportunities as a part of this program: we observe in syndrome specific support groups and clinics, tour genetic laboratories, and are matched with a family with a genetic disease to learn what it is like to live with a genetic condition. Finally, our directors are genuinely invested in each of us, and care about our success and getting to know each of us personally."




  • "The director and assistant director do their best to ensure that our program provides a collaborative learning experience.  Both are active members of the Genetic Counseling community and strive to introduce you to all aspects of this field.  We also have renowned clinical sites and the beautiful state of North Carolina at our disposal.”